ANIP News and Press, ANI Pharmaceuticals Inc. From 03/15/22

ANI Pharmaceuticals press release (NASDAQ:ANIP): Q4 GAAP EPS of $0.54 beats by $0.68. Revenue of $60.9M (+6.3% Y/Y) beats by $4.6M. Cash and cash equivalents were $100.3 million, net accounts receivable was $128.5 million, and face value of debt was $300.0 million as of December 31, 2021. Gui...

-- Fourth quarter net revenues of $60.9 million; net loss of $24.1 million and diluted loss per share of $1.72 -- -- Fourth quarter adjusted non-GAAP EBITDA of $16.2 million and adjusted non-GAAP diluted earnings per share of $0.54 -- -- Full year 2021 revenues of $216...

ANI Pharmaceuticals (NASDAQ:ANIP) is scheduled to announce Q4 earnings results on Tuesday, March 15th, before market open. The consensus EPS Estimate is $0.74 (-7.5% Y/Y) and the consensus Revenue Estimate is $56.3M (-1.7% Y/Y). Over the last 2 years, ANIP has beaten EPS estimates 63% of the ...

ANIP, ATNX, BBI, OTCQX:CCHWF, CTRN, DOLE, DTIL, GMDA, KMDA, KNDI, KPLT, NRP, OTCPK:RWEOY, SYRS For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Tuesday's open

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022. Nikhil Lalwani, President and Chief Executive Officer, and ...

Oakrum Pharma and ANI Pharmaceuticals Announce the Launch of Betaine Anhydrous Powder, the first Generic Version of Cystadane® (betaine anhydrous for oral solution) Powder, Including 180 Days of Exclusivity PR Newswire SAINT LOUIS , Feb. 14, 2022 /PRNewswire...

Today, we revisit specialty pharmaceutical concern ANI Pharmaceuticals for the first time since spring. The company has seen some positive news flow since we last revisited, but the shares of this GARP concern have been held down by the bear market in biotech/biopharma. This has l...

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced the U.S. commercial availability of Purified Cortrophin™ Gel (Repository Corticotropin Injection USP) 80 U/mL. The commercial launch of Cortrophin Gel, an adrenocorticotropic hormone (ACTH), also kn...

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present virtually at the H.C. Wainwright Bioconnect Conference as follows: The webcast will be accessible on d...

ANI Pharmaceuticals (NASDAQ:ANIP) is trading ~3.7% higher in the pre-market on below-average volume after announcing the FDA approval of its Abbreviated New Drug Application for Rifabutin Capsules USP, 150 mg. ANI’s newly approved Rifabutin capsules are a generic version of t...